<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02989753</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01178-43</org_study_id>
    <nct_id>NCT02989753</nct_id>
  </id_info>
  <brief_title>Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia</brief_title>
  <acronym>Lipiback</acronym>
  <official_title>Pilot Study to Assess Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valbiotis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biofortis Mérieux NutriSciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valbiotis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a pilot study in order to estimate the effect of VAL070-A and&#xD;
      VAL070-B products and their variability on LDL cholesterol and lipid metabolism since these&#xD;
      data are still unknown for these products and in this specific population. Collected data&#xD;
      will provide more reliable information which may be used to plan a subsequent larger main&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective&#xD;
&#xD;
      The primary objective of the present trial is to assess the beneficial effect of VAL070-B&#xD;
      compared to a placebo, on blood LDL cholesterol level in moderate hypercholesterolemic and&#xD;
      hypertriglyceridemic subjects after 12 weeks of consumption.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
      Secondary objectives of the study are to assess the effects of VAL070-A and VAL070-B,&#xD;
      compared to a placebo and to each other, in moderate hypercholesterolemic and&#xD;
      hypertriglyceridemic subjects after 12 weeks if consumption through the following parameters:&#xD;
&#xD;
        -  Blood level of LDL cholesterol (VAL070-A compared to placebo and VAL070-A compared to&#xD;
           VAL070-B),&#xD;
&#xD;
        -  Lipid profile: Blood levels of triglycerides, total cholesterol, HDL-cholesterol and&#xD;
           non- HDL cholesterol,&#xD;
&#xD;
        -  Glycaemia,&#xD;
&#xD;
        -  Blood hsCRP,&#xD;
&#xD;
        -  Fructosamine,&#xD;
&#xD;
        -  Blood total free fatty acid levels,&#xD;
&#xD;
        -  Anthropometrics assessed by body weight (BW), waist circumference (WC), hip&#xD;
           circumference (HC) and waist to hip ratio (WHR).&#xD;
&#xD;
      Safety objectives&#xD;
&#xD;
      The following parameters, analyzed at baseline and after 12 weeks of consumption,&#xD;
      participated to the safety objectives:&#xD;
&#xD;
        -  Blood levels of urea and creatinine,&#xD;
&#xD;
        -  Blood levels of GGT, AST and ALT,&#xD;
&#xD;
        -  Complete blood count,&#xD;
&#xD;
        -  Hemodynamic measurements: heart rate (HR), systolic blood pressure (SBP) and diastolic&#xD;
           blood pressure (DBP),&#xD;
&#xD;
        -  Adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between VAL070-B and placebo on changes between V1 and V2 visits of the fasting blood LDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between VAL070-A and placebo on changes between V1 and V2 visits of the fasting blood LDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of triglycerides</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of total cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of HDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of non-HDL cholesterol</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of hsCRP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of fructosamine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of total free fatty acid</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in waist circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hip circumference</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in waist to hip ratio</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of urea</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of creatinine</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in µmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of AST (Aspartate aminotransferase)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in µkat/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of ALT (Alanine aminotransferase)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in µkat/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood concentrations of GGT (Gamma glutamyltransferase)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in µkat/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in complete blood count</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in bpm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Defined as the difference V2 (12 weeks) - V1 (baseline) in mmHg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAL070-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAL070-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VAL070-A</intervention_name>
    <description>After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.</description>
    <arm_group_label>VAL070-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VAL070-B</intervention_name>
    <description>After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.</description>
    <arm_group_label>VAL070-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 70 years (limits included),&#xD;
&#xD;
          -  BMI between 18.5 and 40 kg/m2 (limits included),&#xD;
&#xD;
          -  For women: Non menopausal with the same reliable contraception since at least 3 cycles&#xD;
             before the beginning of the study and agreeing to keep it during the entire duration&#xD;
             of the study (condom with spermicide gel and estrogen/progestin combination&#xD;
             contraception accepted) or menopausal without or with hormone replacement therapy&#xD;
             (estrogenic replacement therapy begun from less than 3 months excluded),&#xD;
&#xD;
          -  Weight stable within ± 5 % in the last three months,&#xD;
&#xD;
          -  Non smoking or with tobacco consumption &lt; 20 cigarettes / day,&#xD;
&#xD;
          -  Good general and mental health with in the opinion of the investigator: no clinically&#xD;
             significant and relevant abnormalities of medical history or physical examination,&#xD;
&#xD;
          -  Able and willing to participate to the study by complying with the protocol procedures&#xD;
             as evidenced by his dated and signed informed consent form,&#xD;
&#xD;
          -  Affiliated with a social security scheme,&#xD;
&#xD;
          -  Agree to be registered on the volunteers in biomedical research file.&#xD;
&#xD;
        After V1 biological analysis the subjects will be eligible to the study on the following&#xD;
        criteria:&#xD;
&#xD;
          -  Fasting blood LDLc level (using Friedewald estimation method) between 1.3 and 2.2 g/L&#xD;
             (limits included with ± 2 % tolerated around),&#xD;
&#xD;
          -  Fasting blood triglycerides level &gt; 1.5 g/L,&#xD;
&#xD;
          -  Blood TSH level between 0.27 and 4.2 μIU/mL (limits included).&#xD;
&#xD;
        Within 3 months following to the exit of the study for failure to comply to one or more of&#xD;
        the inclusion criteria listed above, a re-screening could be performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble&#xD;
             or other metabolic disorder,&#xD;
&#xD;
          -  Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or&#xD;
             biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other&#xD;
             chronic respiratory trouble, etc.) or gastrointestinal disorders found to be&#xD;
             inconsistent with the conduct of the study by the investigator (e.g. celiac disease),&#xD;
&#xD;
          -  With a history of ischemic cardiovascular event,&#xD;
&#xD;
          -  Having undergone recent surgical procedure (less than 6 months),&#xD;
&#xD;
          -  Suffering from an uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or&#xD;
             diastolic blood pressure ≥ 100 mmHg),&#xD;
&#xD;
          -  With a known or suspected food allergy or intolerance or hypersensitivity to any of&#xD;
             the study products' ingredient,&#xD;
&#xD;
          -  Pregnant or lactating women or intending to become pregnant within 3 months ahead,&#xD;
&#xD;
          -  For women: pregnancy or breastfeeding finished since less than 6 months,&#xD;
&#xD;
          -  Under cholesterol and/or lipid-lowering treatment (e.g. statins, fibrates, ezetimibe,&#xD;
             bile acid sequestrants, niacin, etc.) or stopped less than 3 months before the V1&#xD;
             visit,&#xD;
&#xD;
          -  Requiring a cholesterol lowering by immediate pharmacologic intervention according to&#xD;
             the current recommendations (AFSSAPS, 2005),&#xD;
&#xD;
          -  Under medication which could affect blood lipid parameters (e.g. long-term&#xD;
             corticosteroid systemic drug, systemic antibodies, androgens or enzyme inducer, etc.)&#xD;
             or stopped less than 3 months before the randomization (antihypertensive stable&#xD;
             long-term treatment tolerated),&#xD;
&#xD;
          -  Regular intake of dietary supplements or &quot;functional foods&quot; which are known to have an&#xD;
             impact on lipid metabolism (e.g. rich in plant stanol or sterol like PRO-ACTIV or&#xD;
             DANACOL products, red yeast rice, policosanol, capsules containing omega-3 fatty acids&#xD;
             from fish oils, containing beta glucanes, konjac extract or cinnamon, etc.) or stopped&#xD;
             less than 3 months before the V1 visit,&#xD;
&#xD;
          -  Under treatment or dietary supplement which could significantly affect parameter(s)&#xD;
             followed during the study according to the investigator or stopped in a too short&#xD;
             period before the V1 visit,&#xD;
&#xD;
          -  With significant change in food habits or in physical activity in the 3 months before&#xD;
             the V1 visit or not agreeing to keep them unchanged throughout the study,&#xD;
&#xD;
          -  With a current or planned in the next 3 months specific diet (hyper or hypocaloric,&#xD;
             vegan, vegetarian...) or stopped less than 3 months before the study,&#xD;
&#xD;
          -  With a personal history of anorexia nervosa, bulimia or significant eating disorders&#xD;
             according to the investigator,&#xD;
&#xD;
          -  Consuming more than 3 standard drinks of alcoholic beverage daily for men or 2 daily&#xD;
             for women or not agreeing to keep his alcohol consumption habits unchanged throughout&#xD;
             the study,&#xD;
&#xD;
          -  Having a lifestyle deemed incompatible with the study according to the investigator&#xD;
             including high level physical activity (defined as more than 10 hours of significant&#xD;
             physical activity a week, walking excluded),&#xD;
&#xD;
          -  Who made a blood donation in the 3 months before the V1 visit or intending to make it&#xD;
             within 3 months ahead,&#xD;
&#xD;
          -  Taking part in another clinical trial or being in the exclusion period of a previous&#xD;
             clinical trial,&#xD;
&#xD;
          -  Having received, during the last 12 months, indemnities for clinical trial higher or&#xD;
             equal to 4500 Euros,&#xD;
&#xD;
          -  Under legal protection (guardianship, wardship) or deprived from his rights following&#xD;
             administrative or judicial decision,&#xD;
&#xD;
          -  Presenting a psychological or linguistic incapability to sign the informed consent,&#xD;
&#xD;
          -  Impossible to contact in case of emergency,&#xD;
&#xD;
        After V1 biological analysis the subjects will be considered as non eligible to the study&#xD;
        on the following criteria:&#xD;
&#xD;
          -  Fasting blood triglycerides &gt; 4 g/L,&#xD;
&#xD;
          -  Fasting glycaemia &gt; 1.26 g/L&#xD;
&#xD;
          -  Blood AST, ALT or GGT &gt; 3xULN (Upper Limit of Normal),&#xD;
&#xD;
          -  Blood urea &gt; 12.11 mmol/L (value corresponding to 1.5xULN) or creatinine &gt; 125 μmol/L,&#xD;
&#xD;
          -  Blood hsCRP &gt; 10 mg/L,&#xD;
&#xD;
          -  Complete blood count with clinically significant abnormality according to the&#xD;
             investigator.&#xD;
&#xD;
        Within 3 months following to the exit of the study for failure to comply to one or more of&#xD;
        the exclusion criteria listed above, a re-screening could be performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David GENDRE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biofortis Mérieux NutriSciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Marie BARD, Dr-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sébastien PELTIER, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valbiotis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biofortis Mérieux NutriSciences Clinical Investigation Center</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>December 8, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2016</study_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02989753
org study id: 2016-A01178-43
nct id: NCT02989753
lead sponsor: 
collaborator: 
has dmc: Yes
This study is designed as a pilot study in order to estimate the effect of VAL070-A and
      VAL070-B products and their variability on LDL cholesterol and lipid metabolism since these
      data are still unknown for these products and in this specific population. Collected data
      will provide more reliable information which may be used to plan a subsequent larger main
      study.
Main objective

      The primary objective of the present trial is to assess the beneficial effect of VAL070-B
      compared to a placebo, on blood LDL cholesterol level in moderate hypercholesterolemic and
      hypertriglyceridemic subjects after 12 weeks of consumption.

      Secondary objectives

      Secondary objectives of the study are to assess the effects of VAL070-A and VAL070-B,
      compared to a placebo and to each other, in moderate hypercholesterolemic and
      hypertriglyceridemic subjects after 12 weeks if consumption through the following parameters:

        -  Blood level of LDL cholesterol (VAL070-A compared to placebo and VAL070-A compared to
           VAL070-B),

        -  Lipid profile: Blood levels of triglycerides, total cholesterol, HDL-cholesterol and
           non- HDL cholesterol,

        -  Glycaemia,

        -  Blood hsCRP,

        -  Fructosamine,

        -  Blood total free fatty acid levels,

        -  Anthropometrics assessed by body weight (BW), waist circumference (WC), hip
           circumference (HC) and waist to hip ratio (WHR).

      Safety objectives

      The following parameters, analyzed at baseline and after 12 weeks of consumption,
      participated to the safety objectives:

        -  Blood levels of urea and creatinine,

        -  Blood levels of GGT, AST and ALT,

        -  Complete blood count,

        -  Hemodynamic measurements: heart rate (HR), systolic blood pressure (SBP) and diastolic
           blood pressure (DBP),

        -  Adverse events.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Comparison between VAL070-B and placebo on changes between V1 and V2 visits of the fasting blood LDL cholesterol
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Comparison between VAL070-A and placebo on changes between V1 and V2 visits of the fasting blood LDL cholesterol
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Changes in fasting blood concentrations of triglycerides
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Changes in fasting blood concentrations of total cholesterol
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Changes in fasting blood concentrations of HDL cholesterol
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Changes in fasting blood concentrations of non-HDL cholesterol
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Changes in fasting blood concentrations of glucose
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in g/L
measure: Changes in fasting blood concentrations of hsCRP
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in mg/L
measure: Changes in fasting blood concentrations of fructosamine
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in µmol/L
measure: Changes in fasting blood concentrations of total free fatty acid
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in mmol/L
measure: Changes in body weight
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in kg
measure: Changes in waist circumference
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in cm
measure: Changes in hip circumference
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in cm
measure: Changes in waist to hip ratio
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline)
measure: Changes in fasting blood concentrations of urea
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in mmol/L
measure: Changes in fasting blood concentrations of creatinine
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in µmol/L
measure: Changes in fasting blood concentrations of AST (Aspartate aminotransferase)
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in µkat/L
measure: Changes in fasting blood concentrations of ALT (Alanine aminotransferase)
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in µkat/L
measure: Changes in fasting blood concentrations of GGT (Gamma glutamyltransferase)
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in µkat/L
measure: Changes in complete blood count
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline)
measure: Changes in heart rate
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in bpm
measure: Changes in systolic blood pressure
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in mmHg
measure: Changes in diastolic blood pressure
time frame: 12 weeks
description: Defined as the difference V2 (12 weeks) - V1 (baseline) in mmHg
arm group label: Placebo
arm group type: Placebo Comparator
description: The comparative product is a placebo with the same characteristics of appearance and packaging as studied products and in which all ingredients are replaced by maltodextrin.
arm group label: VAL070-A
arm group type: Experimental
description: Studied active product n°1, named VAL070-A, is a dietary supplement in shape of capsule. VAL070-A product contains 4 active plant extracts.
arm group label: VAL070-B
arm group type: Experimental
description: Studied active product n°2, named VAL070-B, is a dietary supplement in shape of capsule. VAL070-B product contains 5 active plant extracts.
intervention type: Dietary Supplement
intervention name: VAL070-A
description: After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
arm group label: VAL070-A
intervention type: Dietary Supplement
intervention name: VAL070-B
description: After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
arm group label: VAL070-B
intervention type: Dietary Supplement
intervention name: Placebo
description: After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
arm group label: Placebo
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: Accepts Healthy Volunteers
last name: David GENDRE, Dr
role: Principal Investigator
affiliation: Biofortis Mérieux NutriSciences
last name: Jean-Marie BARD, Dr-PhD
role: Study Chair
affiliation: UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France
last name: Sébastien PELTIER, PhD
role: Study Director
affiliation: Valbiotis
facility: 
country: France
responsible party type: Sponsor
mesh term: Hypercholesterolemia
mesh term: Hypertriglyceridemia
sharing ipd: Undecided